The concern of generic challenges has long loomed above copyright’s famous drug, Viagra, sparking questions about the outlook of similar medicinal investments. While initial years saw significant returns, the intellectual property lapse has created the path for less expensive substitutes, potentially lowering profitability and creating a real ris